1
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
2
|
Harder J and Opitz OG: Gastric cancer -
risk factors and medical therapy. Praxis. 95:1021–1028. 2006.(In
German). View Article : Google Scholar : PubMed/NCBI
|
3
|
Fuchs CS, Tomasek J, Yong CJ, Dumitru F,
Passalacqua R, Goswami C, Safran H, dos Santos LV, Aprile G, Ferry
DR, et al: REGARD Trial Investigators: Ramucirumab monotherapy for
previously treated advanced gastric or gastro-oesophageal junction
adenocarcinoma (REGARD): An international, randomised, multicentre,
placebo-controlled, phase 3 trial. Lancet. 383:31–39. 2014.
View Article : Google Scholar : PubMed/NCBI
|
4
|
Ligtenberg MJ, Kuiper RP, Chan TL,
Goossens M, Hebeda KM, Voorendt M, Lee TY, Bodmer D, Hoenselaar E,
Hendriks-Cornelissen SJ, et al: Heritable somatic methylation and
inactivation of MSH2 in families with Lynch syndrome due to
deletion of the 3′ exons of TACSTD1. Nat Genet. 41:112–117.
2009. View
Article : Google Scholar : PubMed/NCBI
|
5
|
Bang YJ, Van Cutsem E, Feyereislova A,
Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T,
et al: ToGA Trial Investigators: Trastuzumab in combination with
chemotherapy versus chemotherapy alone for treatment of
HER2-positive advanced gastric or gastro-oesophageal junction
cancer (ToGA): A phase 3, open-label, randomised controlled trial.
Lancet. 376:687–697. 2010. View Article : Google Scholar : PubMed/NCBI
|
6
|
Roder JD, Böttcher K, Busch R, Wittekind
C, Hermanek P and Siewert JR: German Gastric Cancer Study Group:
Classification of regional lymph node metastasis from gastric
carcinoma. Cancer. 82:621–631. 1998. View Article : Google Scholar : PubMed/NCBI
|
7
|
Chen J, Cheong JH, Yun MJ, Kim J, Lim JS,
Hyung WJ and Noh SH: Improvement in preoperative staging of gastric
adenocarcinoma with positron emission tomography. Cancer.
103:2383–2390. 2005. View Article : Google Scholar : PubMed/NCBI
|
8
|
O'Hayre M, Vázquez-Prado J, Kufareva I,
Stawiski EW, Handel TM, Seshagiri S and Gutkind JS: The emerging
mutational landscape of G proteins and G-protein-coupled receptors
in cancer. Nat Rev Cancer. 13:412–424. 2013. View Article : Google Scholar : PubMed/NCBI
|
9
|
Wang HJ, Zhou M, Jia L, Sun J, Shi HB, Liu
SL and Wang ZZ: Identification of aberrant chromosomal regions in
human breast cancer using gene expression data and related gene
information. Med Sci Monit. 21:2557–2566. 2015. View Article : Google Scholar : PubMed/NCBI
|
10
|
Lo FY, Chang JW, Chang IS, Chen YJ, Hsu
HS, Huang SF, Tsai FY, Jiang SS, Kanteti R, Nandi S, et al: The
database of chromosome imbalance regions and genes resided in lung
cancer from Asian and Caucasian identified by array-comparative
genomic hybridization. BMC Cancer. 12:2352012. View Article : Google Scholar : PubMed/NCBI
|
11
|
Cannon-Albright LA, Teerlink CC, Farnham
JM, Thomas AW, Zone JJ and Leachman SA: Linkage analysis of
extended high-risk pedigrees replicates a cutaneous malignant
melanoma predisposition locus on chromosome 9q21. J Invest
Dermatol. 133:128–134. 2013. View Article : Google Scholar : PubMed/NCBI
|
12
|
Koh Y, Park I, Sun CH, Lee S, Yun H, Park
CK, Park SH, Park JK and Lee SH: Detection of a distinctive genomic
signature in rhabdoid glioblastoma, a rare disease entity
identified by whole exome sequencing and whole transcriptome
sequencing. Transl Oncol. 8:279–287. 2015. View Article : Google Scholar : PubMed/NCBI
|
13
|
Vaqué JP, Dorsam RT, Feng X,
Iglesias-Bartolome R, Forsthoefel DJ, Chen Q, Debant A, Seeger MA,
Ksander BR, Teramoto H, et al: A genome-wide RNAi screen reveals a
Trio-regulated Rho GTPase circuitry transducing mitogenic signals
initiated by G protein-coupled receptors. Mol Cell. 49:94–108.
2013. View Article : Google Scholar : PubMed/NCBI
|
14
|
Van Raamsdonk CD, Griewank KG, Crosby MB,
Garrido MC, Vemula S, Wiesner T, Obenauf AC, Wackernagel W, Green
G, Bouvier N, et al: Mutations in GNA11 in uveal melanoma. N
Engl J Med. 363:2191–2199. 2010. View Article : Google Scholar : PubMed/NCBI
|
15
|
Lee CH, Park D, Wu D, Rhee SG and Simon
MI: Members of the Gq α subunit gene family
activate phospholipase C β isozymes. J Biol Chem. 267:16044–16047.
1992.PubMed/NCBI
|
16
|
Rozengurt E: Mitogenic signaling pathways
induced by G protein-coupled receptors. J Cell Physiol.
213:589–602. 2007. View Article : Google Scholar : PubMed/NCBI
|
17
|
Cobb MH and Goldsmith EJ: How MAP kinases
are regulated. J Biol Chem. 270:14843–14846. 1995. View Article : Google Scholar : PubMed/NCBI
|
18
|
Karin M: The regulation of AP-1 activity
by mitogen-activated protein kinases. J Biol Chem. 270:16483–16486.
1995. View Article : Google Scholar : PubMed/NCBI
|
19
|
Dhawan P and Richmond A: A novel NF-kappa
B-inducing kinase-MAPK signaling pathway up-regulates NF-kappa B
activity in melanoma cells. J Biol Chem. 277:7920–7928. 2002.
View Article : Google Scholar : PubMed/NCBI
|
20
|
Kortylewski M, Heinrich PC, Kauffmann ME,
Böhm M, MacKiewicz A and Behrmann I: Mitogen-activated protein
kinases control p27/Kip1 expression and growth of human melanoma
cells. Biochem J. 357:297–303. 2001. View Article : Google Scholar : PubMed/NCBI
|
21
|
Roberts PJ and Der CJ: Targeting the
Raf-MEK-ERK mitogen-activated protein kinase cascade for the
treatment of cancer. Oncogene. 26:3291–3310. 2007. View Article : Google Scholar : PubMed/NCBI
|
22
|
Weber JD, Raben DM, Phillips PJ and
Baldassare JJ: Sustained activation of
extracellular-signal-regulated kinase 1 (ERK1) is required for the
continued expression of cyclin D1 in G1 phase. Biochem J.
326:61–68. 1997. View Article : Google Scholar : PubMed/NCBI
|
23
|
Schwartz MA and Assoian RK: Integrins and
cell proliferation: Regulation of cyclin-dependent kinases via
cytoplasmic signaling pathways. J Cell Sci. 114:2553–2560.
2001.PubMed/NCBI
|
24
|
Van Raamsdonk CD, Bezrookove V, Green G,
Bauer J, Gaugler L, O'Brien JM, Simpson EM, Barsh GS and Bastian
BC: Frequent somatic mutations of GNAQ in uveal melanoma and
blue naevi. Nature. 457:599–602. 2009. View Article : Google Scholar : PubMed/NCBI
|
25
|
Lane DP: Cancer. p53, guardian of the
genome. Nature. 358:15–16. 1992. View
Article : Google Scholar : PubMed/NCBI
|
26
|
Liu J, Zhang C and Feng Z: Tumor
suppressor p53 and its gain-of-function mutants in cancer. Acta
Biochim Biophys Sin. 46:170–179. 2014. View Article : Google Scholar : PubMed/NCBI
|
27
|
Riley T, Sontag E, Chen P and Levine A:
Transcriptional control of human p53-regulated genes. Nat Rev Mol
Cell Biol. 9:402–412. 2008. View
Article : Google Scholar : PubMed/NCBI
|
28
|
Mirza A, Wu Q, Wang L, McClanahan T,
Bishop WR, Gheyas F, Ding W, Hutchins B, Hockenberry T, Kirschmeier
P, et al: Global transcriptional program of p53 target genes during
the process of apoptosis and cell cycle progression. Oncogene.
22:3645–3654. 2003. View Article : Google Scholar : PubMed/NCBI
|